DISEASES Of Interest

Comprehensive Research For Diseases of Interest

Improving quality of life by supporting the accessibility of new treatments in research trials.

Diseases of Interest

At LEADER Research, our mission is to advance the understanding and treatment of various diseases through dedicated clinical research. We focus on conditions that significantly impact patients' quality of life.

Disease of Interest

Atopic Dermatitis (Eczema)


Atopic dermatitis (eczema) is a chronic skin condition that causes patches and/or rashes that are red and itchy. It is exacerbated when the skin is dry and cracked. Atopic dermatitis is commonly associated with allergies and asthma.

Disease of Interest

Hidradenitis Suppurativa


Hidradenitis suppurativa is a chronic skin condition that results in boil-like lumps that frequently develop and leak on the areas of the body where skin rubs together, such as the armpits, groin region, and under the breasts.

Disease of Interest

Chronic Spontaneous Urticaria (Hives)


Chronic Spontaneous Urticaria (Hives) is a condition causing recurrent itchy hives and swelling without a known trigger, lasting for six weeks or more.

Disease of Interest

Chronic Inducible Urticaria (CIndU): Dermographism, Cold, And Cholinergic


Chronic Inducible Urticaria (CIndU)  includes types like dermographism, cold urticaria, and cholinergic urticaria, where hives are triggered by physical stimuli like skin pressure, cold temperatures, or heat and exercise.

Disease of Interest

Nonsegmental Vitiligo


Nonsegmental vitiligo is a skin condition characterized by the loss of pigment in patches, often symmetrically, due to the immune system attacking pigment-producing cells.

Disease of Interest

Alopecia Areata


Alopecia areata is an autoimmune condition that causes sudden, patchy hair loss on the scalp and other parts of the body. The immune system attacks hair follicles, leading to hair thinning or bald patches.

Disease of Interest

Plaque Psoriasis


Psoriasis is a chronic autoimmune skin condition that results in itchy, dry, raised skin patches (plaques) covered with gray or silver scales, commonly affecting the knees, elbows, trunk, and scalp, frequently, causing discomfort. 

Actively Recruiting Trials

  • Between 12 and 64 years old

CLINICAL TRIAL

RECRUITING

Atopic Dermatitis

(Eczema) Trial

Phase 2 | Injection | 32 weeks


  • ≥ 18 years old

Trial ID: NCT06015308

CLINICAL TRIAL

RECRUITING

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT05995964

Phase 2 | Injection | 12 weeks


  • ≥ 18 years old

CLINICAL TRIAL

RECRUITING

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT06241118

Phase 3 | Injection | 52 weeks


  • ≥ 12 years old

CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Trial ID: NCT05889182

Phase 3 | Oral tablet | 108 weeks

RECRUITING


  • ≥ 12 years old

CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Phase 2 | Injection | 32 weeks

Trial ID: NCT06118099

RECRUITING


  • Between 18 and 70 years old

CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Phase 3 | Oral tablet | 54 weeks

Trial ID: NCT06212999

RECRUITING


  • ≥ 18 years old

CLINICAL TRIAL

RECRUITING

Nonsegmental Vitiligo Trial

Trial ID: NCT06113445

Phase 3 | Oral tablet | 52 weeks


  • ≥ 18 years olds

CLINICAL TRIAL

RECRUITING

Plaque Psoriasis

Trial

Trial ID: NCT06550076

Phase 3 | Oral tablet | 64 weeks


  • ≥ 18 years old

CLINICAL TRIAL

Chronic Spontaneous Urticaria

(Hives) Trial

Phase 3b | Oral tablet | 52 weeks

Trial ID: NCT06042478

RECRUITING


  • ≥ 18 years old

CLINICAL TRIAL

RECRUITING

Chronis Inducible Urticaria (CIndU): Dermographism Cold, And Cholinergic Trial

Trial ID: NCT05976243

Phase 3 | Oral tablet | 56 weeks


  • ≥ 18 years old

CLINICAL TRIAL

RECRUITING

Alopecia Areata

Trial

Trial ID: NCT06444451

Phase 2 | Injection | 52 weeks


  • ≥ 18 years old

CLINICAL TRIAL

Alopecia Areata

Trial

Phase 3 | Oral tablet | 160 weeks

Trial ID: NCT06012240

RECRUITING


  • Between 12 and 64 years old

CLINICAL TRIAL

RECRUITING

Hidradenitis Suppurativa Trial

Trial ID: NCT06468228

Phase 3 | Injection | 16-62 weeks


  • ≥ 16 years old

CLINICAL TRIAL

RECRUITING

Chronic Spontaneous

Urticaria

(Hives) Trial

Trial ID: NCT06455202

Phase 3 | Injection | 52 weeks


  • ≥ 18 years old

CLINICAL TRIAL

RECRUITING

Hidradenitis Suppurativa Trial

Trial ID: NCT06603077

Phase 2 | Injection | 24 weeks


  • ≥ 18 years old

Currently Not Recruiting

Trial ID: NCT05398445

CLINICAL TRIAL

CONTACT US TO LEARN MORE

CLINICAL TRIAL

CLOSED

Atopic Dermatitis

(Eczema) Trial

Phase 3 | Injection | 52 weeks


Trial ID: NCT05633355

CLINICAL TRIAL

CLOSED

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT05398445

Phase 3 | Injection | 24 weeks


CLINICAL TRIAL

CLOSED

Plaque Psoriasis

Trial

Trial ID: NCT03982394

Phase 1 | Injection | 156 weeks


CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Trial ID: NCT05889182

Phase 3 | Oral tablet | 108 weeks

CLOSED


CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Phase 2 | Injection | 32 weeks

Trial ID: NCT06118099

CLOSED


CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Phase 3 | Oral tablet | 54 weeks

Trial ID: NCT06212999

CLOSED


CLINICAL TRIAL

Atopic Dermatitis

(Eczema) Trial

Phase 3 | Injection | 52 weeks

Trial ID: NCT06224192

CLOSED


CLINICAL TRIAL

CLOSED

Plaque Psoriasis

Trial

Trial ID: NCT06108544

Phase 3 | Oral tablet | 64 weeks


CLINICAL TRIAL

CLOSED

Nonsegmental Vitiligo Trial

Trial ID: NCT06118411

Phase 3 | Oral tablet | 48-112 weeks


Trials Coming Soon (placeholder)

CLINICAL TRIAL

UPCOMING

Disease Of Interest

Trial

Phase X | Injection | XX week treatment period | XX week safety follow up


  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

Trial ID: XXXXXXXXXXX

Exclusion Criteria:

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

CLINICAL TRIAL

UPCOMING

Disease Of Interest

Trial

Trial ID: XXXXXXXXXXX

Phase X | Injection | XX week treatment period | XX week safety follow up


  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

Exclusion Criteria:

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

CLINICAL TRIAL

UPCOMING

Disease Of Interest

Trial

Trial ID: XXXXXXXXXXX

Phase X | Injection | XX week treatment period | XX week safety follow up


  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

Exclusion Criteria:

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit